As the validation of regenerative medicine grows nearer using embryonic (hESC) and induced (iPSC) stem cells to treat unmet medical needs. www.investorstemcell.com is dedicated to bringing investors and stakeholders together in thoughtful discussion to educate and publicize the incredible advancements in the regenerative medicine sector. The worldâ€™s only encompassing on-line source for regenerative medicine. iCELL is providing the latest news, discussion forums and educational material at no cost to its members. Investing on facts and not hype:
Online PR News – 05-July-2011 – – This third quarter is shaping up to be the most exciting yet in regenerative medicine. The science using stem cells is rapidly evolving and so is public policy. In the United States a bill, sponsored by Rep. Diana DeGette (D-Colo.), would give legislative backing to President Obamaâ€™s 2009 executive order. Pennsylvania Republican Rep. Charlie Dent is co-sponsor of the embryonic stem cell legislation, offering key Republican support for a controversial bill reviled by many social conservatives. Jonathan Thomas an investment banker with an interest in biology has been chosen to be the new chairman of Californiaâ€™s $3 billion stem cell research program. A founding partner of Saybrook Capital, Mr. Thomas will be bringing an investment approach to the CIRM program in hopes of lessoning the burden on tax payers during a time when the stateâ€™s fiscal crisis could jeopardize financing for the effort.
Companies on the move in publicly traded markets:
Advanced Cell Technology (OTC:ACTC) applies stem cell-based technologies. Two clinical trials under way using embryonic stem cells to treat Stargardt's disease and Dry Age-Related Macular Degeneration. AMD is the worldâ€™s #1 unmet medical need. First trial report in October 2011. Raymond Lund, Ph.D., a scientific collaborator with ACT, and considered one of the world's foremost experts in retinal cell physiology and vision restoration, commented, "The study results of ACT's RPE cells implanted in the various animal models of macular degeneration was phenomenal. If ACT observes even a fraction of that benefit in humans, it will be nothing short of a home run."
Geron Corporation (NASDAQ:GERN) is a biopharmaceutical company that is developing biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. Conducting a trial in patients with spinal cord injury.
BioTime, Inc. (AMEX:BTX)is stem cell company using technology and products for use in regenerative medicine. These products and technologies are being developed and marketed by our wholly owned subsidiary Embryome Sciences, Inc.
Aastrom Biosciences (NASDAQ:ASTM) is a leader in the development of enhanced autologous cellular therapies for use in the treatment of severe, chronic cardiovascular diseases.
Mesoblast limited (ASX:MSB)is an Australian biotechnology company committed to the development of novel treatments for orthopedic conditions, including the commercialization of unique adult stem cells to regenerate and repair bone and cartilage.
Life Technologies Corporation (NASDAQ:LIFE) is a global life sciences company. Life Technologies delivers a range of products and services, including systems, instruments, reagents, software, and custom services.
Pfizer Inc. (NYSE:PFE) is a research-based, global biopharmaceutical company. The Company is invested in dozens of regenerative medicine applications including, cancer, heart and blood.
International Stem Cell Corp (OTC:ISCO) has developed a process to derive stem cells similar to Embryonic Stem Cells without the need for fertilized embryos and with minimal exposure to non-human cells. These factors provide ISC a unique leadership role in the field of regenerative cell therapy.
Investor Stem Cell is following over 50 niche companies in the regenerative medicine sector. Stem Cell Media, LLC. Nor any of its Companies has been compensated for this press release.